Tempus AI and Stemline Therapeutics partner to advance AI-driven ESR1 mutation testing in metastatic breast cancer
Tempus AI, Inc. (NASDAQ: TEM) and Stemline Therapeutics, Inc., a wholly owned subsidiary of the Menarini Group, have announced a collaboration to integrate Tempus Next, ... Read More
Tempus AI stock soars 14% after FDA approval of xT CDx test
Tempus AI, a leader in healthcare technology, has unveiled its FDA-approved in vitro diagnostic device, xT CDx, marking a pivotal step forward in precision oncology. ... Read More
Tempus AI shakes up precision medicine with $600m acquisition of Ambry Genetics
Tempus AI has taken a significant step in advancing its precision medicine strategy by agreeing to acquire Ambry Genetics in a $600 million deal. This ... Read More